Sustained virological response and its treatment predictors in hepatitis C virus genotype 4 compared to genotypes 1, 2, and 3: A meta-Analysis

BMJ Open Gastroenterology

Volumn 2, Issue 1, 2015, Pages

  Yee, Brittany E ^a   Nguyen, Nghia H ^a   Zhang, Bing ^a   Lin, Derek ^b   Vutien, Philip ^c   Wong, Carrie R ^d   Lutchman, Glen A ^b   Nguyen, Mindie H ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d Northwell Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL OUTCOME; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; SUSTAINED VIROLOGIC RESPONSE; TREATMENT RESPONSE;

EID: 84964411332     PISSN: None     EISSN: 20544774     Source Type: Journal    
DOI: 10.1136/bmjgast-2015-000049     Document Type: Article

References (107)

1. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999;6:35-47.
2. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-67.
3. Wantuck JM, Ahmed A, Nguyen MH. Review article: The epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Aliment Pharmacol Ther 2014;39:137-47.
4. Wise M, Bialek S, Finelli L, et al. Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology 2008;47:1128-35.
5. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 2009;49:1335-74.
6. Hnatyszyn HJ. Chronic hepatitis C and genotyping: The clinical significance of determining HCV genotypes. Antivir Ther 2005;10:1-11.
7. Kamal SM, Ahmed A, Mahmoud S, et al. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis. Liver Int 2011;31:401-11.
8. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
9. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-65.
10. Abdo AA, Al-Ahdal MN, Khalid SS, et al. IL28B polymorphisms predict the virological response to standard therapy in patients with chronic hepatitis C virus genotype 4 infection. Hepatol Int 2013;7:533-8.
11. Afifi MT, El-Gohary A. Evaluation of the efficacy and safety of pegylated interferon (alpha)2a 160 mg (reiferon retard) and ribavirin combination in chronic HCV genotype 4 patients. J Gastroenterol Hepatol 2010;25(Suppl 2):A95.
12. Ahmed MM, Abdel-Salam OME, Mohammed NA, et al. Oxidative status and the response to pegylated-interferon alpha2a plus ribavirin in chronic genotype 4 HCV hepatitis. EXCLI J 2013;12:605-15.
13. Al-Ashgar HI, Khan MQ, Helmy A, et al. Relationship of interferon-gamma-inducible protein-10 kDa with viral response in patients with various heterogeneities of hepatitis C virus genotype-4. Eur J Gastroenterol Hepatol 2013;25:404-10.
14. Al-Enzi SA, Ismail WA, Alsurayei SA, et al. Peginterferon alfa-2b and ribavirin therapy in Kuwaiti patients with chronic hepatitis C virus infection. East Mediterr Health J 2011;17:669-78.
15. Antaki N, Bibert S, Kebbewar K, et al. IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4. J Viral Hepat 2013;20:59-64.
16. Asselah T, De Muynck S, Broet P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2012;56:527-32.
17. De Nicola S, Aghemo A, Rumi MG, et al. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology 2012;55:336-42.
18. Derbala M, Amer A, Bener A, et al. Pegylated interferon-Alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis. J Viral Hepat 2005;12:380-5.
19. Derbala M, Rizk N, Shebl F, et al. Interleukin-28 and hepatitis C virus genotype-4: Treatment-induced clearance and liver fibrosis. World J Gastroenterol 2012;18:7003-8.
20. Derbala M, Rizk NM, Al-Kaabi S, et al. The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients. Virology 2013;444:292-300.
21. Derbala MF, Amer AM, Almohanadi M, et al. Hepatitis C virus genotype 4 with normal transaminases: histological changes, schistosomiasis and response to treatment. J Viral Hepat 2011;18: E258-e262.
22. Derbala MF, El Dweik NZ, Al Kaabi SR, et al. Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: Ribavirin therapy. J Viral Hepat 2008;15:591-9.
23. El Khayat HR, Fouad YM, Ahmad EA, et al. Hepatitis C virus (genotype 4)-Associated mixed cryoglobulinemia vasculitis: Effects of antiviral treatment. Hepatol Int 2012;6:606-12.
24. El Khayat HR, Fouad YM, El Amin H, et al. A randomized trial of 24 versus 48 weeks of peginterferon alpha-2a plus ribavirin in Egyptian patients with hepatitis C virus genotype 4 and rapid viral response. Trop Gastroenterol 2012;33:112-17.
25. El Makhzangy H, Esmat G, Said M, et al. Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. J Med Virol 2009;81:1576-83.
26. El Raziky M, Fathalah WF, El-Akel WA, et al. The Effect of Peginterferon Alpha-2a vs. Peginterferon Alpha-2b in Treatment of Naive Chronic HCV Genotype-4 Patients: A Single Centre Egyptian Study. Hepat Mon 2013;13:e10069.
27. El-Shamy A, Shoji I, El-Akel W, et al. NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients. J Clin Microbiol 2012;50:3886-92.
28. Eskander EF, Abd-Rabou AA, Yahya SM, et al. Does interferon and ribavirin combination therapy ameliorate growth hormone deficiency in HCV genotype-4 infected patients? Clin Biochem 2012;45:3-6.
29. Esmat G, Fattah SA. Evaluation of a novel pegylated interferon alpha-2a (Reiferon Retard(registered trademark)) in Egyptian patients with chronic hepatitis C-genotype 4. Dig Liver Dis Suppl 2009;3: 17-19 .
30. Farag RE, Arafa MM, El-Etreby S, et al. Human leukocyte antigen class I alleles can predict response to pegylated interferon/ribavirin therapy in chronic hepatitis C Egyptian patients. Arch Iran Med 2013;16:68-73.
31. Gad RR, Males S, El Makhzangy H, et al. Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C. Liver Int 2008;28:1112-19.
32. Hasan F, Asker H, Al-Khaldi J, et al. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol 2004;99:1733-7.
33. Ibrahim M, Gomaa W, Ibrahim Y, et al. Nitric oxide levels and sustained virological response to pegylated-interferon alpha2a plus ribavirin in chronic HCV genotype 4 hepatitis: A prospective study. J Gastrointestin Liver Dis 2010;19:387-92.
34. Kamal SM, El Kamary SS, Shardell MD, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. Hepatology 2007;46:1732-40.
35. Kamal SM, El Tawil AA, Nakano T, et al. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005;54:858-66.
36. Karatapanis S, Dimitroulopoulos D, Papastergiou V, et al. Hepatitis C genotype 4 response rate to pegylated interferon A2A or A2B and ribavirin is similar between caucasians and egyptian patients. Eur J Intern Med 2011;22(Suppl 1):S47.
37. Khairy M, Fouad R, Mabrouk M, et al. The impact of interleukin 28b gene polymorphism on the virological response to combined pegylated interferon and ribavirin therapy in chronic HCV genotype 4 infected Egyptian patients using data mining analysis. Hepat Mon 2013;13:e10509.
38. Khattab M, Eslam M, Sharwae MA, et al. Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients. Am J Gastroenterol 2010;105:1970-7.
39. Khattab MA, Eslam M, Shatat M, et al. Changes in adipocytokines and insulin sensitivity during and after antiviral therapy for hepatitis C genotype 4. J Gastrointestin Liver Dis 2012;21:59-65.
40. Lopez-Alonso G, Agreda M, Devesa MJ, et al. [Results of the treatment of chronic hepatitis C genotype 4-A comparative analysis with genotype 1]. Rev Esp Enferm Dig 2008;100: 208-11.
41. Mahmoud M, El-Tokhy S, El-Lebedy D, et al. Peripheral blood lymphocytes' DNA damage in different treatment outcomes of chronic viral C hepatitis genotype 4 infection. J Med Sci 2013;13:353-9.
42. Marcellin P, Cheinquer H, Curescu M, et al. High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Hepatology 2012;56:2039-50.
43. Mauss S, Berger F, Vogel M, et al. Treatment results of chronic hepatitis C genotype 5 and 6 infections in Germany. Z Gastroenterol 2012;50:441-4.
44. Monis A, Ali Monis A, Al Swaff R. Virologic response at week 8 of combined treatment as a predictor of sustained virologic response in non rapid virologic response, chronic HCV genotype 4 infected patients. Egypt J Med Hum Genet 2012;13:331-5.
45. Moucari R, Ripault MP, Martinot-Peignoux M, et al. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut 2009;58:1662-9.
46. Njouom R, Sartre MT, Timba I, et al. Efficacy and safety of peginterferon alpha-2a/ribavirin in treatment-naive Cameroonian patients with chronic hepatitis C. J Med Virol 2008;80:2079-85.
47. Omran MH, Ibrahim NE, Youssef SS, et al. Relation of interleukin-1beta gene to treatment response in chronic patients infected with HCV genotype 4. J Infect Dev Ctries 2013;7:851-8.
48. Papastergiou V, Dimitroulopoulos D, Skorda L, et al. Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: does ethnicity matter? J Med Virol 2012;84:1217-23.
49. Pasha HF, Radwan MI, Hagrass HA, et al. Cytokines genes polymorphisms in chronic hepatitis C: impact on susceptibility to infection and response to therapy. Cytokine 2013;61:478-84.
50. Ragheb MM, Nemr NA, Kishk RM, et al. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4. Liver Int 2014;34:890-5.
51. Saad Y, Ahmed A, Saleh DA, et al. Adipokines and insulin resistance, predictors of response to therapy in Egyptian patients with chronic hepatitis C virus genotype 4. Eur J Gastroenterol Hepatol 2013;25:920-5.
52. Saad Y, Said M, Nassar Y, et al. Microsomal Triglyceride Transfer Protein (MTP) polymorphisms as marker for prediction of response to antiviral therapy in Egyptian patients with chronic HCV genotype 4. Hepatology 2012;56(Suppl 1):1005A.
53. Shahin Y, Metwally MA, Shaheen W, et al. A scoring model for prediction of relapse among chronic HCV genotype 4 patients treated with peg interferon and ribavirin. J Hepatol 2013;58(Suppl 1): S358-9.
54. Shaker O, El-Shehaby A, Fayez S, et al. Osteopontin gene polymorphisms as predictors for the efficacy of interferon therapy in chronic hepatitis C Egyptian patients with genotype 4. Cell Biochem Funct 2013;31:620-5.
55. Shaker OG, Sadik NA. Polymorphisms in interleukin-10 and interleukin-28B genes in Egyptian patients with chronic hepatitis C virus genotype 4 and their effect on the response to pegylated interferon/ribavirin-Therapy. J Gastroenterol Hepatol 2012;27: 1842-9.
56. Shiha G, El-Etrby S, Zalata K, et al. Efficacy of new PEG-interferon a-2a (Reiferon Retard(registered trademark)) plus ribavirin in egyption patients with chronic hepatitis C genotyp 4. Hepatol Int 2010;4:187-8.
57. Stauber RE, Scherzer T, Putz-Bankuti CM, et al. Baseline vitamin D levels do not influence SVR in patients with chronic HCV genotype 1 or 4 infection undergoing peginterferon/ribavirin treatment. J Hepatol 2011;54(Suppl 1):S468-S469.
58. Taha AA, El-Ray A, El-Ghannam M, et al. Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis C. Can J Gastroenterol 2010;24:597- 602.
59. Urquijo JJ, Diago M, Boadas J, et al. Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4. Ann Hepatol 2013;12:30-5.
60. Deeks JJ, Higgins JPT, Altman DG, eds. Chapter 9: Analysing data and undertaking meta-Analyses. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration. 2011. Available from www.cochrane-handbook.org.
61. Abdel-Rahman M, Saad Y, El-Raziky M, et al. Hepatitis C genotype 4 with normal transaminases: correlation with fibrosis and response to treatment, a cohort Egyptian study of 4277 patients. Clin Res Hepatol Gastroenterol 2013;37:479-84.
62. Akbar HO, Al Ghamdi A, Qattan F, et al. Chronic hepatitis C in Saudi Arabia: Three years local experience in a university hospital. Hepat Mon 2012;12:e6178.
63. Al Ali J, Owayed S, Al-Qabandi W, et al. Pegylated interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4 in adolescents. Ann Hepatol 2010;9:156-60.
64. Al Ashgar H, Helmy A, Khan MQ, et al. Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4. Ann Saudi Med 2009;29:4-14.
65. Al Ashgar HI, Khan MQ, Al-Ahdal M, et al. Hepatitis C genotype 4: genotypic diversity, epidemiological profile, and clinical relevance of subtypes in Saudi Arabia. Saudi J Gastroenterol 2013;19:28-33.
66. Al-Ali J, Siddique I, Varghese R, et al. Pegylated interferon-Alpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT. Ann Hepatol 2012;11:186-93.
67. Alfaleh FZ, Alswat K, Helmy A, et al. The natural history and long-Term outcomes in patients with chronic hepatitis C genotype 4 after interferon-based therapy. Liver Int 2013;33:871-83.
68. Derbala M, Amer A, Shebl F, et al. Neutropenia and viral load decline during treatment of hepatitis C virus genotype-4 patients: The paradox of treatment modification. Hepatol Int 2012;6:194.
69. Derbala MF, Al Kaabi SR, El Dweik NZ, et al. Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage. World J Gastroenterol 2006;12:5692-8.
70. Diago M, Hassanein T, Rodes J, et al. Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-Alpha2a and ribavirin. Ann Intern Med 2004;140:72-3.
71. Elefsiniotis IS, Pavlidis C, Dimitroulopoulos D, et al. Differential viral kinetics in treated genotype 4 chronic hepatitis C patients according to ethnicity. J Viral Hepat 2009;16:738-42.
72. Elefsiniotis IS, Pavlidis C, Ketikoglou I, et al. Patient's age modifies the impact of the proposed predictors of sustained virological response in chronic hepatitis C patients treated with PEG-interferon plus ribavirin. Eur J Intern Med 2008;19:266-70.
73. Elefsiniotis IS, Vezali E, Mihas C, et al. Predictive value of complete and partial early virological response on sustained virological response rates of genotype-4 chronic hepatitis C patients treated with PEG-interferon plus ribavirin. Intervirology 2009;52:247-51.
74. El-Khattib AA, Abdelhakam SM, Ghoraba DM, et al. Outcome of antiviral therapy in Egyptian Hepatitis C Virus (HCV) genotype 4 patients with advanced liver fibrosis. Eur J Intern Med 2012;23: E34-e35.
75. Fathalla W, El-Akel W, Salama A, et al. The effect of peginterferon alpha-2a vs. Peginterferon alpha-2B in treatment of naive chronic HCV genotype-4 patients: A cohort egyptian study. Gastroenterology 2012;142(5 Suppl. 1):S939.
76. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008;135:451-8.
77. Elsayed-Elbatae H. Could vitamin D supplementation improve response to antiviral treatment for hepatitis C virus genotype 4? Hepatol Int 2013;7(Suppl 1):S343.
78. Hamdi N, El-Akel W, El-Serafy M, et al. Transcriptional response of MxA, PKR and SOCS3 to interferon-based therapy in HCV genotype 4-infected patients and contribution of p53 to host antiviral response. Intervirology 2012;55:210-18.
79. Kamal S, Ghoraba D, Nabegh L, et al. Pegylated interferon alfa-2a vs pegylated interferon alfa-2b, plus ribavirin, for chronic hepatitis C genotype 4 patients: A randomized controlled trial. Hepatology 2009;50(Suppl 4):1025A-1026A.
80. Khattab MA, Abdel-Fattah ME, Eslam M, et al. Hepatic steatosis in genotype 4 chronic hepatitis C patients: implication for therapy. J Clin Gastroenterol 2010;44:707-12.
81. Legrand-Abravanel F, Nicot F, Boulestin A, et al. Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. J Med Virol 2005;77:66-9.
82. Mimidis K, Papadopoulos VP, Elefsiniotis I, et al. Hepatitis C virus survival curve analysis in naive patients treated with peginterferon alpha-2b plus ribavirin. A randomized controlled trial for induction with high doses of peginterferon and predictability of sustained viral response from early virologic data. J Gastrointestin Liver Dis 2006;15:213-19.
83. Roulot D, Bourcier V, Grando V, et al. Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 2007;14:460-7.
84. Shaker O, Ahmed A, Doss W, et al. MxA expression as marker for assessing the therapeutic response in HCV genotype 4 Egyptian patients. J Viral Hepat 2010;17:794-9.
85. Shaker O, Bassiony H, El Raziky M, et al. Human leukocyte antigen class II alleles (DQB1 and DRB1) as predictors for response to interferon therapy in HCV genotype 4. Mediators Inflamm 2013;2013:392-746.
86. Shaker OG, Eskander EF, Yahya SM, et al. Genetic variation in BCL-2 and response to interferon in hepatitis C virus type 4 patients. Clin Chim Acta 2011;412:593-8.
87. Shiha G, Samir W, Seif S, et al. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients with hepatitis C virus genotype 4. Hepatology 2012;56 (Suppl 1):1023A.
88. Taha A, Hasan M, El-Ray A, et al. Impact of cigarette smoking on the sustained viral response to treatment with pegylated interferon alpha-2a and ribavirin combination in male patients with chronic Hepatitis C Genotype 4. Hepatol Int 2012;6:187.
89. Velosa J, Serejo F, Bana T, et al. Chronic hepatitis C treated with peginterferon alfa plus ribavirin in clinical practice. Hepatogastroenterology 2011;58:1260-6.
90. Zayed N, Awad AB, El-Akel W, et al. The assessment of data mining for the prediction of therapeutic outcome in 3719 Egyptian patients with chronic hepatitis C. Clin Res Hepatol Gastroenterol 2013;37:254-61.
91. Zayed N, Esmat G, Elakel WA, et al. Therapeutic outcome in 6198 interferon-naive Egyptian patients with chronic hepatitis C genotype-4: A real experience. Hepatology 2012;56(Suppl 1):1016A.
92. Zeidan A, El-Etreby S, Bahgat M, et al. Pulmonary changes following the combination therapy of peginterferon alpha-2a and ribavirin for chronic hepatitis C genotype 4 infection. Hepatol Int 2012;6:196.
93. Zekri AR, Haleem HA, Esmat GE, et al. Immunomodulators, sFas and Fas-L as potential noninvasive predictors of IFN treatment in patients with HCV genotype-4. J Viral Hepat 2007;14:468-77.
94. European Association for Study of L. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014;60:392-420.
95. Sovaldi [package insert]. 2013. http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi-pi.pdf.
96. Harvoni [package insert]. 2014http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni-pi.pdf.
97. Viekira Pak [package insert]. 2014. http://www.abbvie.com/content/dam/abbviecorp/us/desktop/contentrooms/downloads/ProductFactsheet-ViekiraPak-US.pdf.
98. Organization WH. Guidelines for the screening, care, and treatment of persons with hepatitis C infection 2014. [cited 27 Sep 2014]. http://apps.who.int/iris/bitstream/10665/111747/1/9789241548755-eng.pdf?ua=1.
99. Rao P, Koshy A, Philip J, et al. Pegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C. World J Hepatol 2014;6:520-6.
100. Bonardi R, Tabone M, Manca A, et al. Short duration treatment in genotype 1 chronic hepatitis C patients with rapid virologic response to pegylated interferon plus ribavirin. Biomed Pharmacother 2011;65:303-6.
101. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-17.
102. Yu JW, Wang GQ, Sun LJ, et al. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 2007;22:832-6.
103. Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial. Hepatology 2008;47:1884-93.
104. Dalgard O, Bjoro K, Ring-Larsen H, et al. Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology 2008;47:35-42.
105. Lagging M, Langeland N, Pedersen C, et al. Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008;47:1837-45.
106. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357:124-34.
107. von Wagner M, Huber M, Berg T, et al. Peginterferon-Alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129:522-7.